NORTH CHICAGO, Ill., Aug. 18, 2021 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2021 Thriving Undergraduate and Thriving Graduate Scholarship. At the conclusion of this voting period, two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system, will be awarded scholarships totaling $25,000 each for use towards higher education.
NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
NORTH CHICAGO, Ill., March 17, 2021 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting applications for the 2021-2022 academic school year. Eligible undergraduate and graduate students are invited to apply for the scholarship until April 30, 2021 at 11:00 a.m. U.S. eastern time by visiting www.AbbVieCFScholarship.com. Students can apply online or by downloading an application on the official scholarship website.
NORTH CHICAGO, Ill., Sept. 16, 2020 /PRNewswire/ -- AbbVie today announced the start of its annual public voting period for the 2020 Thriving Undergraduate and Thriving Graduate Scholarship. Following this voting period, scholarships totaling $25,000 each will be given to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.
NORTH CHICAGO, Ill., April 8, 2020 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting applications for the 2020-2021 academic school year. Undergraduate and graduate students are invited to apply for the scholarship until May 24, 2020 by visiting www.AbbVieCFScholarship.com. Eligible students can apply online or by downloading an application on the official scholarship website.
NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and the Cystic Fibrosis Foundation, announced today a strategic collaboration in which AbbVie will develop a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator compound licensed from the Foundation. Under the terms of the agreement, AbbVie will advance the potentiator into clinical development for potential use in combination treatments for cystic fibrosis (CF).
NORTH CHICAGO, Ill., Sept. 25, 2019 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced the start of its public voting period for the 2019 Thriving Undergraduate and Thriving Graduate Scholarship. Following this voting period, scholarships totaling $25,000 each will be given to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.
NORTH CHICAGO, Ill., March 28, 2018 /PRNewswire/ -- AbbVie, a global research and development-based biopharmaceutical company, today announced that the 2018 AbbVie CF Scholarship program is now accepting applications for the 2018-2019 academic school year. Undergraduate and graduate students are invited to apply for the scholarship now until May 9, 2018 at 10:00 a.m. U.S. Central time by visiting www.AbbVieCFScholarship.com. Students can apply online or by downloading an application on the scholarship website.
Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?
